New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2013
06:01 EDTCELGCelgene price target raised to $104 from $94 at Jefferies
Jefferies raised its estimates and price target for Celgene citing the company's new 2017 guidance, which the firm says reflects stronger than expected operating margin leverage. Jefferies keeps a Buy rating on Celgene, which was upgraded this morning at both RBC Capital and Piper Jaffray.
News For CELG From The Last 14 Days
Check below for free stories on CELG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2014
08:59 EDTCELGOn The Fly: Pre-Market Movers
Subscribe for More Information
07:41 EDTCELGCelgene reports Q1 REVLIMID sales $1.14B
The company said, "REVLIMID sales for the Q1 increased 14% to $1.14B and were driven by overall market share, increased duration of therapy and geographic expansion. U.S. sales of $642M and International sales of $502M increased 13% and 16%, respectively. ABRAXANE sales for Q1 were $185M, a 51% increase. U.S. sales of $142M and International sales of $43M increased 51% and 49%, respectively. The increase in sales reflects the impact of the ongoing U.S. launch in pancreatic cancer and early launch success for pancreatic cancer in Europe."
07:40 EDTCELGCelgene reaffirms 2014 adjusted EPS, sales guidance
Subscribe for More Information
07:40 EDTCELGCelgene sees 2014 adjusted EPS $7.00-$7.20, consensus $7.29
Subscribe for More Information
07:38 EDTCELGCelgene reports Q1 adjusted EPS $1.67, consensus $1.65
Subscribe for More Information
April 23, 2014
16:44 EDTCELGAcceleron, Celgene announce interim clinical data for sotatercept
Subscribe for More Information
15:35 EDTCELGNotable companies reporting before tomorrow's open
Subscribe for More Information
07:41 EDTCELGAlliqua to launch Biovance human amniotic membrane allograft product
Alliqua (ALQA) will launch its Biovance human amniotic membrane allograft product. Biovance was originally developed by, and is currently being manufactured through a supply agreement with, Celgene Cellular Therapeutics, a subsidiary of Celgene (CELG), to assist wound care specialists, physicians and nurses, as well as vascular, plastic and general surgeons, in the treatment of a wide variety of complex, acute, chronic, recalcitrant, full and partial thickness wound types. With the right to develop and market Biovance, Alliqua has entered into one of the fastest-growing areas of wound care, which involves regenerative medicine. Alliqua will commence sales of Biovance immediately following the Symposium via its team of direct sales representatives.
April 22, 2014
07:40 EDTCELGCelgene weakness has created attractive entry point, says Stifel
Subscribe for More Information
April 16, 2014
08:34 EDTCELGPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
April 11, 2014
09:03 EDTCELGCelgene shares can unlock big value, says RBC Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use